These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38362622)

  • 1. 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).
    Skowronski DM; Zhan Y; Kaweski SE; Sabaiduc S; Khalid A; Olsha R; Carazo S; Dickinson JA; Mather RG; Charest H; Jassem AN; Levade I; Hasso M; Zelyas N; Gao R; Bastien N
    Euro Surveill; 2024 Feb; 29(7):. PubMed ID: 38362622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).
    Valenciano M; Kissling E; Reuss A; Jiménez-Jorge S; Horváth JK; Donnell JM; Pitigoi D; Machado A; Pozo F;
    Vaccine; 2015 Jun; 33(24):2813-22. PubMed ID: 25936723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings: A test-negative case-control study in Beijing, China, 2016/17 season.
    Wu S; Pan Y; Zhang X; Zhang L; Duan W; Ma C; Zhang Y; Zhang M; Sun Y; Yang P; Wang Q; Ma J
    Vaccine; 2018 Sep; 36(38):5774-5780. PubMed ID: 30087046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay JB; Drews SJ; Martineau C; Charest H; Krajden M; Bastien N; Li Y
    J Infect Dis; 2017 Dec; 216(12):1487-1500. PubMed ID: 29029166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study.
    Kissling E; Pozo F; Martínez-Baz I; Buda S; Vilcu AM; Domegan L; Mazagatos C; Dijkstra F; Latorre-Margalef N; Kurečić Filipović S; Machado A; Lazar M; Casado I; Dürrwald R; van der Werf S; O'Donnell J; Linares Dopido JA; Meijer A; Riess M; Višekruna Vučina V; Rodrigues AP; Mihai ME; Castilla J; Goerlitz L; Falchi A; Connell J; Castrillejo D; Hooiveld M; Carnahan A; Ilić M; Guiomar R; Ivanciuc A; Maurel M; Omokanye A; Valenciano M;
    Influenza Other Respir Viruses; 2023 Jan; 17(1):e13069. PubMed ID: 36702797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016.
    Chambers C; Skowronski DM; Sabaiduc S; Winter AL; Dickinson JA; De Serres G; Gubbay JB; Drews SJ; Martineau C; Eshaghi A; Krajden M; Bastien N; Li Y
    Euro Surveill; 2016; 21(11):30168. PubMed ID: 27020673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23.
    Skowronski DM; Chuang ES; Sabaiduc S; Kaweski SE; Kim S; Dickinson JA; Olsha R; Gubbay JB; Zelyas N; Charest H; Bastien N; Jassem AN; De Serres G
    Euro Surveill; 2023 Feb; 28(5):. PubMed ID: 36729117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study.
    Maurel M; Pozo F; Pérez-Gimeno G; Buda S; Sève N; Oroszi B; Hooiveld M; Gomez V; Domegan L; Martínez-Baz I; Ilić M; Carnahan AS; Mihai ME; Martínez A; Goerlitz L; Enouf V; Horváth JK; Dijkstra F; Rodrigues AP; Bennett C; Trobajo-Sanmartín C; Mlinarić I; Latorre-Margalef N; Ivanciuc A; Lopez A; Dürrwald R; Falchi A; Túri G; Meijer A; Melo A; O'Donnell J; Castilla J; Vučina VV; Hagey TS; Lazar M; Kaczmarek M; Bacci S; Kissling E;
    Influenza Other Respir Viruses; 2024 Jan; 18(1):e13243. PubMed ID: 38204584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.
    Kim S; Chuang ES; Sabaiduc S; Olsha R; Kaweski SE; Zelyas N; Gubbay JB; Jassem AN; Charest H; De Serres G; Dickinson JA; Skowronski DM
    Euro Surveill; 2022 Sep; 27(38):. PubMed ID: 36148674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of influenza vaccine in preventing medically-attended influenza virus infection in primary care, Israel, influenza seasons 2014/15 and 2015/16.
    Yaron-Yakoby H; Sefty H; Pando R; Dichtiar R; Katz MA; Stein Y; Mandelboim M; Mendelson E; Shohat T; Glatman-Freedman A;
    Euro Surveill; 2018 Feb; 23(7):. PubMed ID: 29471622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.
    Skowronski DM; Chambers C; Sabaiduc S; Dickinson JA; Winter AL; De Serres G; Drews SJ; Jassem A; Gubbay JB; Charest H; Balshaw R; Bastien N; Li Y; Krajden M
    Euro Surveill; 2017 Feb; 22(6):. PubMed ID: 28205503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay J; Fonseca K; Charest H; Krajden M; Petric M; Mahmud SM; Van Caeseele P; Bastien N; Eshaghi A; Li Y
    J Infect Dis; 2015 Sep; 212(5):726-39. PubMed ID: 25784728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV).
    Skowronski DM; Sabaiduc S; Leir S; Rose C; Zou M; Murti M; Dickinson JA; Olsha R; Gubbay JB; Croxen MA; Charest H; Bastien N; Li Y; Jassem A; Krajden M; De Serres G
    Euro Surveill; 2019 Nov; 24(46):. PubMed ID: 31771709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13.
    Kissling E; Valenciano M; Buchholz U; Larrauri A; Cohen JM; Nunes B; Rogalska J; Pitigoi D; Paradowska-Stankiewicz I; Reuss A; Jiménez-Jorge S; Daviaud I; Guiomar R; O'Donnell J; Necula G; Głuchowska M; Moren A
    Euro Surveill; 2014 Feb; 19(6):. PubMed ID: 24556348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.
    Rose AMC; Pozo F; Martínez-Baz I; Mazagatos C; Bossuyt N; Cauchi JP; Petrović G; Loghin II; Vaikutyte R; Buda S; Machado A; Duffy R; Oroszi B; Howard J; Echeverria A; Andreu C; Barbezange C; Džiugytė A; Nonković D; Popescu CP; Majauskaite F; Tolksdorf K; Gomez V; Domegan L; Horváth JK; Castilla J; García M; Demuyser T; Borg ML; Tabain I; Lazar M; Kubiliute I; Dürrwald R; Guiomar R; O'Donnell J; Kristóf K; Nicolay N; Bacci S; Kissling E; ;
    Influenza Other Respir Viruses; 2024 Feb; 18(2):e13255. PubMed ID: 38403302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine.
    McLean HQ; Caspard H; Griffin MR; Gaglani M; Peters TR; Poehling KA; Ambrose CS; Belongia EA
    JAMA Netw Open; 2018 Oct; 1(6):e183742. PubMed ID: 30646262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza vaccine effectiveness in Italy: Age, subtype-specific and vaccine type estimates 2014/15 season.
    Rizzo C; Bella A; Alfonsi V; Puzelli S; Palmieri AP; Chironna M; Pariani E; Piatti A; Tiberti D; Ghisetti V; Rangoni R; Colucci ME; Affanni P; Germinario C; Castrucci MR
    Vaccine; 2016 Jun; 34(27):3102-3108. PubMed ID: 27154392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.
    Valenciano M; Kissling E; Reuss A; Rizzo C; Gherasim A; Horváth JK; Domegan L; Pitigoi D; Machado A; Paradowska-Stankiewicz IA; Bella A; Larrauri A; Ferenczi A; ; Lazar M; Pechirra P; Korczyńska MR; Pozo F; Moren A;
    Euro Surveill; 2016; 21(7):pii=30139. PubMed ID: 26924024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of the current and prior influenza vaccinations in Northern Spain, 2018-2019.
    Castilla J; Portillo ME; Casado I; Pozo F; Navascués A; Adelantado M; Gómez Ibáñez C; Ezpeleta C; Martínez-Baz I;
    Vaccine; 2020 Feb; 38(8):1925-1932. PubMed ID: 31982263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding influenza vaccine protection in the community: an assessment of the 2013 influenza season in Victoria, Australia.
    Carville KS; Grant KA; Sullivan SG; Fielding JE; Lane CR; Franklin L; Druce J; Kelly HA
    Vaccine; 2015 Jan; 33(2):341-5. PubMed ID: 25448093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.